NAPSA and adenocarcinoma: In patients with non-adenocarcinoma, ELF-napsin A at the nodule site was 2041 (398–5108) ng∙mL−1, and that at the contralateral site was 1719 (425–4186) ng∙mL−1, indicating no significant difference (P = 0.463, Fig. 4a).